双特异性抗体治疗合约製造市场－全球产业规模、份额、趋势、机会和预测（按适应症、给药途径、最终用途、地区和竞争细分，2020-2030 年预测）

2024年，全球双特异性抗体治疗合约製造市场规模达73.2亿美元，预计2030年将达到187.4亿美元，年复合成长率达16.92%。双特异性抗体因其能够同时靶向两种不同抗原的能力，在生物製药行业备受瞩目，为癌症和自体免疫疾病等复杂疾病提供了新的治疗策略。合约製造组织 (CMO) 在这一领域发挥着至关重要的作用，它们提供生产这些复杂生物製剂所需的基础设施、技术专长和可扩展性。快速扩张的双特异性抗体候选药物管线，以及许多生物製药公司倾向于外包的专业化製造能力需求，共同推动市场的发展。随着企业不断开发创新的双特异性抗体形式和治疗应用，对灵活、高品质製造支援的需求预计将稳定成长，这将进一步强化CMO在推动下一代生物疗法发展中的作用。

关键市场驱动因素

双特异性抗体疗法的持续研究活动

主要市场挑战

双特异性抗体疗法生产面临的挑战

主要市场趋势

双特异性抗体的需求不断增加

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球双特异性抗体治疗合约製造市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按适应症（癌症、传染病、自体发炎和自体免疫疾病、中枢神经系统疾病、其他）
  • 依给药途径（静脉注射、皮下注射、其他）
  • 依最终用途（製药公司、生物製药公司、其他）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美双特异性抗体治疗合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲双特异性抗体治疗合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区双特异性抗体治疗合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲双特异性抗体治疗合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲双特异性抗体治疗合约製造市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Lonza Group AG
• Creative Biolabs Inc
• Amgen Inc
• Johnson & Johnson
• Wuxi Biologics Cayman Inc
• Roche Holding AG
• Sino Biological Inc
• IQVIA Inc
• Janssen Pharmaceuticals Inc
• AbbVie Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Bispecific Antibody Therapeutics Contract Manufacturing Market was valued at USD 7.32 billion in 2024 and is projected to reach USD 18.74 billion by 2030, growing at a CAGR of 16.92%. Bispecific antibodies have gained significant traction in the biopharmaceutical industry for their ability to target two different antigens simultaneously, offering novel therapeutic strategies for complex diseases such as cancer and autoimmune disorders. Contract manufacturing organizations (CMOs) play a crucial role in this landscape by providing the infrastructure, technical expertise, and scalability required to manufacture these complex biologics. The market is being driven by a rapidly expanding pipeline of bispecific antibody candidates and the need for specialized manufacturing capabilities that many biopharma companies prefer to outsource. As companies continue to develop innovative bispecific formats and therapeutic applications, the demand for flexible, high-quality manufacturing support is expected to rise steadily, reinforcing the role of CMOs in advancing next-generation biologic therapies.

Key Market Drivers

Ongoing Research Activities in Bispecific Antibody Therapeutics

The Global Bispecific Antibody Therapeutics Contract Manufacturing Market is experiencing strong growth due to intensifying research and development efforts. As of early 2025, there are more than 200 bispecific antibody candidates in various stages of development, with over 50 undergoing clinical trials targeting oncology, autoimmune conditions, and infectious diseases. The structural diversity of bispecific formats-such as BiTEs, DVD-Igs, and tandem diabodies-requires advanced design and production capabilities. CMOs with expertise in bispecific antibody manufacturing are increasingly in demand as they provide essential services like high-throughput analytics, improved purification processes, and scalable production systems. With more than 60% of biologics-focused CMOs having expanded capabilities tailored to bispecifics, the sector is seeing a surge in specialized offerings aimed at supporting the growing complexity and volume of these novel therapeutics.

Key Market Challenges

Challenges Associated with Manufacturing of Bispecific Antibody Therapeutics

Manufacturing bispecific antibody therapeutics presents a unique set of challenges that differentiate them from traditional monoclonal antibodies. The complexity of these molecules-arising from their dual-target structure-necessitates precise control over manufacturing to ensure consistency and efficacy. Post-translational modifications such as glycosylation and oxidation introduce further heterogeneity, requiring robust analytical oversight. Scale-up remains a critical hurdle, as production must transition smoothly from development to commercial levels without compromising quality. Custom purification strategies are often required due to the distinct molecular properties of each bispecific antibody, complicating downstream processing. Additionally, the need for specialized equipment, such as bioreactors and chromatography systems suited for bispecifics, results in higher capital investment. Regulatory compliance adds another layer of complexity, as evolving global guidelines demand rigorous quality and safety controls, further elevating the operational demands for CMOs in this field.

Key Market Trends

Increasing Demand for Bispecific Antibodies

The rising demand for bispecific antibodies is a dominant trend shaping the Global Bispecific Antibody Therapeutics Contract Manufacturing Market. These molecules offer the ability to engage two targets simultaneously, providing novel mechanisms of action in diseases like cancer, autoimmune disorders, and infections. In oncology, bispecific T-cell engagers (BiTEs) have shown strong therapeutic potential by redirecting immune responses toward cancer cells, prompting further clinical exploration. The trend toward personalized medicine is also driving demand for customizable bispecific formats tailored to specific disease subtypes or patient groups. As biopharmaceutical companies seek contract partners capable of delivering precision-engineered therapeutics at scale, the market for CMOs offering flexible and advanced bispecific antibody manufacturing continues to grow. This rising demand, coupled with innovations in therapeutic design, is positioning bispecific antibodies as a key area of growth within the broader biologics manufacturing ecosystem.

Key Market Players

• Lonza Group AG
• Creative Biolabs Inc
• Amgen Inc
• Johnson & Johnson
• Wuxi Biologics Cayman Inc
• Roche Holding AG
• Sino Biological Inc
• IQVIA Inc
• Janssen Pharmaceuticals Inc
• AbbVie Inc

Report Scope:

In this report, the Global Bispecific Antibody Therapeutics Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bispecific Antibody Therapeutics Contract Manufacturing Market, By Indication:

• Cancer
• Infectious Diseases
• Autoinflammatory and Autoimmune Diseases
• CNS Conditions
• Others

Bispecific Antibody Therapeutics Contract Manufacturing Market, By Route of Administration:

• Intravenous
• Subcutaneous
• Others

Bispecific Antibody Therapeutics Contract Manufacturing Market, By End Use:

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others

Bispecific Antibody Therapeutics Contract Manufacturing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibody Therapeutics Contract Manufacturing Market.

Available Customizations:

Global Bispecific Antibody Therapeutics Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customers

5. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Infectious Diseases, Autoinflammatory and Autoimmune Diseases, CNS Conditions, Others)
  • 5.2.2. By Route of Administration (Intravenous, Subcutaneous, Others)
  • 5.2.3. By End Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indications
  • 6.2.2. By Route of Administration
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indications
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By End Use
  • 6.3.2. Mexico Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indications
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By End Use
  • 6.3.3. Canada Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indications
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By End Use

7. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indications
  • 7.2.2. By Route of Administration
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indications
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By End Use
  • 7.3.2. Germany Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indications
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indications
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indications
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indications
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indications
  • 8.2.2. By Route of Administration
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indications
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indications
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End Use
  • 8.3.3. South Korea Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indications
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End Use
  • 8.3.4. Japan Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indications
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indications
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By End Use

9. South America Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indications
  • 9.2.2. By Route of Administration
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indications
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indications
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indications
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indications
  • 10.2.2. By Route of Administration
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indications
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indications
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indications
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Lonza Group AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Product & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Creative Biolabs Inc
• 15.3. Amgen Inc
• 15.4. Johnson & Johnson
• 15.5. Wuxi Biologics Cayman Inc
• 15.6. Roche Holding AG
• 15.7. Sino Biological Inc
• 15.8. IQVIA Inc
• 15.9. Janssen Pharmaceuticals Inc
• 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer